Prima BioMed announces CVac granted fast track designation by FDA
moreView todays social media effects on PBMDView the latest stocks trending across Twitter. Click to view dashboardSee who Prima is hiring next, click here to view […]
PBMD
Prima BioMed’s CVac(TM) Granted Fast Track Designation by FDA
[Marketwired] – Prima BioMed Ltd is pleased to announce today that the United States Food and Drug Administration granted Fast Track Designation to the CVac clinical development program at Prima. This program is intended … moreView todays social media effects on PBMDView the latest stocks trending across Twitter. Click to view dashboardSee who Prima is hiring next, click here to […]
Prima BioMed to Present at 13th Annual Needham Healthcare Conference
[Marketwired] – Prima BioMed Ltd today announced that its Chief Executive Officer, Matthew Lehman, will present at the 13th Annual Needham Healthcare Conference on Wednesday, April 9, 2014 at 2:20 p.m. U.S. Eastern time … moreView todays social media effects on PBMDView the latest stocks trending across Twitter. Click to view dashboardSee who Prima is hiring next, click here to […]
Prima BioMed’s CVac(TM) Data Demonstrating Improvement in PFS in Second Remission Ovarian Cancer Accepted for Oral Presentation at ASCO
[Marketwired] – Prima BioMed Ltd announced today that the American Society of Clinical Oncology has accepted the abstract entitled, Progression-free survival in ovarian cancer patients in second remission is improved … moreView todays social media effects on PBMDView the latest stocks trending across Twitter. Click to view dashboardSee who Prima is hiring next, click here to view […]
Prima BioMed to Present at Regen Med Investor Day March 26th in New York
[at noodls] – 27 February 2014 ENGLISH SYDNEY, AUSTRALIA – Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) (Prima, the Company) will present at the 2nd Annual Regen Med Investor Day to be held Wednesday, … moreView todays social media effects on PBMDView the latest stocks trending across Twitter. Click to view dashboardSee who Prima is hiring next, click here to […]
Prima BioMed to Present at 24th Annual Wall Street Analyst Forum Institutional Investor Conference
[at noodls] – 27 February 2014 ENGLISH SYDNEY, AUSTRALIA – Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) (Prima, the Company) will present a corporate overview and provide an update of its CVacâ„¢ … moreView todays social media effects on PBMDView the latest stocks trending across Twitter. Click to view dashboardSee who Prima is hiring next, click here to view […]
Prima BioMed to Present at Regen Med Investor Day March 26th in New York
[Marketwired] – Prima BioMed Ltd will present at the 2nd Annual Regen Med Investor Day to be held Wednesday, March 26, 2014 in New York City. moreView todays social media effects on PBMDView the latest stocks trending across Twitter. Click to view dashboardSee who Prima is hiring next, click here to view […]
Prima BioMed to Present at 24th Annual Wall Street Analyst Forum Institutional Investor Conference
[Marketwired] – Prima BioMed Ltd will present a corporate overview and provide an update of its CVacâ„¢ development program at the 24th Annual Wall Street Analyst Forum Institutional Investor Conference at the University … moreView todays social media effects on PBMDView the latest stocks trending across Twitter. Click to view dashboardSee who Prima is hiring next, click here to view […]
Prima BioMed and Neopharm Group Execute Final Agreement for CVac License
[at noodls] – 21 February 2014 Prima BioMed und die Neopharm Group schließen finale Vereinbarung über CVac-Lizenz ENGLISH Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) (Prima, the Company) is pleased … moreView todays social media effects on PBMDView the latest stocks trending across Twitter. Click to view dashboardSee who Prima is hiring next, click here to view […]
Prima BioMed and Neopharm Group Execute Final Agreement for CVac License
[Marketwired] – Prima BioMed Ltd is pleased to announce that it has finalized an agreement with Neopharm Group for an exclusive license to market and sell CVacâ„¢, a personalized immunocellular therapeutic under investigation … moreView todays social media effects on PBMDView the latest stocks trending across Twitter. Click to view dashboardSee who Prima is hiring next, click here to view […]
